Pemetrexed-containing Regimens Should Be Considered in RET-rearranged Lung Cancers

Share this content:
Pemetrexed-containing regimens should be considered in patients with RET-rearranged lung cancer.
Pemetrexed-containing regimens should be considered in patients with RET-rearranged lung cancer.

Pemetrexed-containing regimens should be considered in patients with RET-rearranged lung cancers, according to a study published in the Annals of Oncology.1

Previous studies have shown clinical benefit with pemetrexed-based therapies in ALK- and ROS1-rearranged cancers, but the efficacy of pemetrexed-based treatments in patients with RET-rearranged lung cancers had not been established.

Therefore, investigators conducted a retrospective review of patients with stage 3b/4 lung adenocarcinomas with RET, ROS1, or ALK rearrangement, or KRAS mutation treated with pemetrexed alone or in combination. The primary endpoint was progression-free survival (PFS), and secondary endpoints included time to progression. Time to treatment discontinuation were compared among RET-rearranged and groups of ROS1-rearranged, ALK-rearranged, and KRAS-mutant lung cancer types.

A total of 104 patients were evaluated. Those with RET-rearranged lung cancers (n = 18) had a median PFS of 19 months (95% CI, 12 – not reached); patients with ROS1-rearrangements (n = 10) had a median PFS of 23 months (95% CI, 14 – not reached); and patients with ALK-rearrangements (n = 36) had a median PFS of 19 months (95% CI, 15 – 36). Patients with KRAS mutations (n = 40) had a median PFS of 6 months (95% CI, 5 – 9; P< .001).

Patients with RET-rearranged lung cancers did not have significantly different overall response rate, median time to progression, and median time to treatment discontinuation than those with ALK- or ROS1-rearrangement cancers, but were improved compared with those with KRAS-mutant lung cancers.

RELATED: Liquid Biopsies Genotype Advanced Lung Cancer Reliably, Swiftly

“Durable benefits with pemetrexed-based therapies in RET-rearranged lung cancers are comparable to ALK- and ROS1-rearranged lung cancers,” the authors concluded.

Reference

  1. Drilon A, Bergagnini I, Delasos L, et al. Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers [published online ahead of print April 7, 2016]. Ann Oncol. doi: 10.1093/annonc/mdw163.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters